5．C型慢性肝炎治療の新たな展開
Saved in:
| Published in | 日本内科学会雑誌 Vol. 103; no. 9; pp. 2084 - 2097 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本内科学会
10.09.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-5384 1883-2083 |
| DOI | 10.2169/naika.103.2084 |
Cover
| Author | 熊田, 博光 |
|---|---|
| Author_xml | – sequence: 1 fullname: 熊田, 博光 organization: 虎の門病院肝臓内科 |
| BookMark | eNo9jz1Lw0Acxg-pYKxd_RQm3v9eksuowTcouOh8XJI7TaxRki5uJuBU6NaCgwougoOoq36b0FQnv4K1isvzPPCDB37LqJWdZRqhVcAOAddfz1RyohzA1CFYsAVkgRDUnm3aQhbGBGxOBVtCnaJIQsyoywVQZqE1_vU-DCa3g-bqvrl8-KhuptWweX2bXld1-dSMn-vyri4fJy-jz_FgBS0a1St056_b6HB76yDYtbv7O3vBRtdOAVxlAxbgMc5xHAkcC5cYQZnHCDChPQaxZyIch5poE4Y-58CMiYUCpn2XGiUwbaPN39-06KsjLc_z5FTlF1Ll_STqaTmXlTNZ6c_zR_kfRscql6mi3zH-X0o |
| ContentType | Journal Article |
| Copyright | 2014 一般社団法人 日本内科学会 |
| Copyright_xml | – notice: 2014 一般社団法人 日本内科学会 |
| DOI | 10.2169/naika.103.2084 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1883-2083 |
| EndPage | 2097 |
| ExternalDocumentID | article_naika_103_9_103_2084_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS DIK F5P JSF OK1 RJT |
| ID | FETCH-LOGICAL-j116a-108174550dc80d862f834742148e741d7fc0dbe2efbb95514ffd8a14e963fa803 |
| ISSN | 0021-5384 |
| IngestDate | Wed Sep 03 06:30:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j116a-108174550dc80d862f834742148e741d7fc0dbe2efbb95514ffd8a14e963fa803 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/naika/103/9/103_2084/_article/-char/ja |
| PageCount | 14 |
| ParticipantIDs | jstage_primary_article_naika_103_9_103_2084_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2014/09/10 |
| PublicationDateYYYYMMDD | 2014-09-10 |
| PublicationDate_xml | – month: 09 year: 2014 text: 2014/09/10 day: 10 |
| PublicationDecade | 2010 |
| PublicationTitle | 日本内科学会雑誌 |
| PublicationTitleAlternate | 日内会誌 |
| PublicationYear | 2014 |
| Publisher | 一般社団法人 日本内科学会 |
| Publisher_xml | – name: 一般社団法人 日本内科学会 |
| References | 19) McPhee F, et al: Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 56: 5387-5396, 2012. 4) Kumada H, et al: Telaprevir with peginterferon and ribavirin fortreatment-naïve patients chronically infectedwith HCV of genotype 1 in Japan. J Hepatol 56: 78-84, 2012. 23) McPhee F, et al: Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56: 3670-3681, 2012. 26) Ge D, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401, 2009. 8) Suzuki F: EASL 2012. Oral 2344. 17) Dore GJ, et al: Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 58: S570-571, 2013. 5) Hayashi N, et al: Efficacy and safety to telaprevir, a new protease inhibitor, for difficult to treat patientswith genotype 1 chronic hepatitis C. J Viral Hepatitis 19: 134-142, 2012. 22) Bronowicki JP, et al: Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013. 21) Everson GT, et al: Interim analysis of an interferon (IFN) -and ribavirin (RBV) -free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients. J Hepatol 58: S573, 2013. 18) Sulkowski MS, et al: High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 56, 2012[Abstract LB02]. 20) Pasquinelli C, et al: Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 56: 1838-1844, 2012. 16) Pol S, et al: Daclatasvir for previously untreated chronic hepatitis C genotype 1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dosefinding, phase 2a trial. Lancet Infect Dis 12: 671-677, 2012. 6) Akuta N, et al: Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin. Hepatology 52: 421-429, 2010. 14) Friborg J, et al: Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother 57: 1312-1322, 2013. 15) Nettles RE, et al: Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54: 1956-1965, 2011. 13) Pelosi LA, et al: Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 56: 5230-5239, 2012. 9) Suzuki Y, et al: Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58: 655-662, 2013. 24) Gane EJ, et al: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44, 2013. 2) 田中純子: 平成24年度肝炎ウイルス感染状況・長期経過と予後調査及び治療導入対策に関する研究; 2014厚生労働科学研究費補助金肝炎等克服緊急対策研究事業. 3) Di Bisceglie AM, et al: Recombination interferon alfa therapy for chronic hepatitis C. A randomized, double-blind placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989. 12) Gao M, et al: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96-100, 2010. 10) Chayama K, et al: Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55: 742-748, 2012. 7) Hayashi N: Oral presentation at JSH 2013. 25) McPhee F, et al: Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology2013. http://dx.doi.org/10.1002/hep.26388. [Epub ahead of print]. 27) Suzuki F, et al: Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 54: 352-354, 2012. 1) 厚生労働省大臣官房統計情報部: 平成20年人口動態統計上・下巻. 2008. 11) Kumada H, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatolog2014. doi: 10.1002/hep.27113 |
| References_xml | – reference: 3) Di Bisceglie AM, et al: Recombination interferon alfa therapy for chronic hepatitis C. A randomized, double-blind placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989. – reference: 24) Gane EJ, et al: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44, 2013. – reference: 5) Hayashi N, et al: Efficacy and safety to telaprevir, a new protease inhibitor, for difficult to treat patientswith genotype 1 chronic hepatitis C. J Viral Hepatitis 19: 134-142, 2012. – reference: 6) Akuta N, et al: Amino acid substitutions in the hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to Telaprevir with peginterferon and ribavirin. Hepatology 52: 421-429, 2010. – reference: 21) Everson GT, et al: Interim analysis of an interferon (IFN) -and ribavirin (RBV) -free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients. J Hepatol 58: S573, 2013. – reference: 25) McPhee F, et al: Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology2013. http://dx.doi.org/10.1002/hep.26388. [Epub ahead of print]. – reference: 2) 田中純子: 平成24年度肝炎ウイルス感染状況・長期経過と予後調査及び治療導入対策に関する研究; 2014厚生労働科学研究費補助金肝炎等克服緊急対策研究事業. – reference: 22) Bronowicki JP, et al: Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013. – reference: 10) Chayama K, et al: Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55: 742-748, 2012. – reference: 13) Pelosi LA, et al: Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 56: 5230-5239, 2012. – reference: 14) Friborg J, et al: Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother 57: 1312-1322, 2013. – reference: 1) 厚生労働省大臣官房統計情報部: 平成20年人口動態統計上・下巻. 2008. – reference: 8) Suzuki F: EASL 2012. Oral 2344. – reference: 26) Ge D, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401, 2009. – reference: 15) Nettles RE, et al: Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54: 1956-1965, 2011. – reference: 20) Pasquinelli C, et al: Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 56: 1838-1844, 2012. – reference: 4) Kumada H, et al: Telaprevir with peginterferon and ribavirin fortreatment-naïve patients chronically infectedwith HCV of genotype 1 in Japan. J Hepatol 56: 78-84, 2012. – reference: 7) Hayashi N: Oral presentation at JSH 2013. – reference: 18) Sulkowski MS, et al: High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 56, 2012[Abstract LB02]. – reference: 9) Suzuki Y, et al: Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58: 655-662, 2013. – reference: 19) McPhee F, et al: Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 56: 5387-5396, 2012. – reference: 16) Pol S, et al: Daclatasvir for previously untreated chronic hepatitis C genotype 1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dosefinding, phase 2a trial. Lancet Infect Dis 12: 671-677, 2012. – reference: 17) Dore GJ, et al: Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 58: S570-571, 2013. – reference: 27) Suzuki F, et al: Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 54: 352-354, 2012. – reference: 11) Kumada H, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatolog2014. doi: 10.1002/hep.27113 – reference: 12) Gao M, et al: Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96-100, 2010. – reference: 23) McPhee F, et al: Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56: 3670-3681, 2012. |
| SSID | ssib043658134 ssj0066765 ssib002821954 ssib005879745 ssib007485360 ssib058493862 ssib000940260 ssib002484664 |
| Score | 2.0136 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 2084 |
| SubjectTerms | C型肝炎 プロテアーゼ阻害薬 ペグインターフェロン リバビリン |
| Title | 5．C型慢性肝炎治療の新たな展開 |
| URI | https://www.jstage.jst.go.jp/article/naika/103/9/103_2084/_article/-char/ja |
| Volume | 103 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本内科学会雑誌, 2014/09/10, Vol.103(9), pp.2084-2097 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1883-2083 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib007485360 issn: 0021-5384 databaseCode: KQ8 dateStart: 19130101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Na9RAdKgVxIv4idYPenBOmppkJskbPE12ZylKBaGF3kKSTQ572IpsL566C54KvVnwoIIXwYOoV_03S7d68i_43iS7mxUPtsISZt_Mm3kz72XmvfDmPcbuBhLPCJFnjoqC3METL3XIjHAKlIVMlFlRSrrvvPEkXN-Sj7aD7aUzvOG1tDvI1vIXf71XchquIgz5SrdkT8DZWacIwDLyF5_IYXz-E48Dbjo8bnEwLW4CrgyHmJuQQ8C1bwsu1xE3wMHnqs1NRAUwVBX7PI4JohQBjUCdkmtbpbDWrSGqM63SNESMEBxVURuIm5qtRYy4DmyhxbUlCSwxOAqSoTyC6DbXITeS6FbadhXbKqAhYPbR1hKL2NrSKIkilAbbZ9siBtRzlRho-tnCk-RjUTuwkqDZcYCWgdYALFFICwKNXbCYa2EXQ9hpIVzj797p5tI8AHzPwT2--oZRVHs-gECxqvLpzA4FVzSkXzW3eHeKXf-t_Iv_PIp8L6RIrn26CEaRDdbmeAvhvWvhSWzDBBsmyj6peTKtpBt4SQ_NgLN-FIaUqOPx04YWrSRFhmtoXbCQNACtaq8Z9S-ASDWTHEQSdbY5vhSolXrzqIGooioB4SwqG3lFV4lB6rWsYqHShB8sThe1uh7aOFP_SKuybV5kF2pba1VX07vElnrpZXZuo_YmucLuB7--H7SO3u5PXr6f7H34MXpzPDqYfP12_Ho0Hn6aHH4eD9-Nhx-Pvrz6ebh_lW11zGZr3amzhzg9zwtTFDZAaxsN8G4ObhfpL0HISPpo_xeoRnejMne7WeEXZZYpshvKsgupJws8ksoUXHGNLfd3-sV1thrhGqncLf0iFLi3QRq4JQW2cyED7ELcYA-reSbPqhAxyUm4uvJf2DfZ-fnrdYstD57vFrdRTx5kd6yU_AbolJAB |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=5%EF%BC%8EC%E5%9E%8B%E6%85%A2%E6%80%A7%E8%82%9D%E7%82%8E%E6%B2%BB%E7%99%82%E3%81%AE%E6%96%B0%E3%81%9F%E3%81%AA%E5%B1%95%E9%96%8B&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E7%86%8A%E7%94%B0%2C+%E5%8D%9A%E5%85%89&rft.date=2014-09-10&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=0021-5384&rft.eissn=1883-2083&rft.volume=103&rft.issue=9&rft.spage=2084&rft.epage=2097&rft_id=info:doi/10.2169%2Fnaika.103.2084&rft.externalDocID=article_naika_103_9_103_2084_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5384&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5384&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5384&client=summon |